A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.

ABSTRACT:

Background

Ixabepilone (BMS-247550), an epothilone B analog, is a microtubule stabilizing agent which has shown activity in several different tumor types and preclinical models in melanoma. In an open label, one-arm, multi-center phase II trial the efficacy and toxicity of this epothilone was investigated in two different cohorts: chemotherapy-naïve (previously untreated) and previously treated patients with metastatic melanoma.

Methodology/principal findings

Eligible patients had histologically-confirmed stage IV melanoma, with an ECOG performance status of 0 to 2. Ixabepilone was administered at a dose of 20 mg/m(2) on days 1, 8, and 15 during each 28-day cycle. The primary endpoint was response rate (RR); secondary endpoints were time to progression (TTP) and toxicity. Tw

SUBMITTER: Ott PA 

PROVIDER: S-EPMC2808339 | biostudies-literature | 2010 Jan

REPOSITORIES: biostudies-literature